PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation

Bone Marrow Transplant. 2017 Feb;52(2):317-320. doi: 10.1038/bmt.2016.274. Epub 2016 Nov 28.

Authors

J C Albring¹, S Inselmann², T Sauer¹, C Schliemann¹, B Altvater³, S Kailayangiri³, C Rössig³, W Hartmann⁴, J R Knorrenschild², K Sohlbach², C Groth¹, M Lohoff², A Neubauer², W E Berdel¹, A Burchert², M Stelljes¹

Affiliations

¹ Department of Medicine A, University Hospital of Muenster, Muenster, Germany.
² Klinik für Hämatologie, Onkologie und Immunologie, Universitätsklinikum Gießen und Marburg, Standort Marburg, Philipps Universität Marburg, Baldingerstraße, Marburg, Germany.
³ Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Münster, Germany.
⁴ Gerhard-Domagk-Institute of Pathology of the University Hospital, Münster, Germany.

PMID: 27892950
DOI: 10.1038/bmt.2016.274

No abstract available

Publication types

Case Reports
Clinical Trial

MeSH terms

Adult
Allografts
Antibodies, Monoclonal / administration & dosage*
Female
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute / metabolism
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Nivolumab
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / metabolism
Recurrence

Substances

Antibodies, Monoclonal
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab